Borthwick Kathleen — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Borthwick Kathleen is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $38K.
Profile
Kathleen Borthwick is the Chief Financial Officer of Passage Bio, Inc., a genetic medicines company focused on rare monogenic CNS disorders. Based on the SEC Form 4 insider filing dated 2026-01-12 (CIK: 0001987062), she reported no purchases or sales of Passage Bio securities in that period. Passage Bio is advancing a pipeline including therapies for GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe disease.
Role
Insider
Notability
40/100
Board memberships
Passage Bio, Inc.
Awards & honors
Oversight of financial operations as CFO for Passage Bio, Inc.
Kathleen Borthwick is the Chief Financial Officer of Passage Bio, Inc., a genetic medicines company focused on rare monogenic CNS disorders. Based on the SEC Form 4 insider filing dated 2026-01-12 (CIK: 0001987062), she reported no purchases or sales of Passage Bio securities in that period. Passage Bio is advancing a pipeline including therapies for GM1 Gangliosidosis, Frontot…
Has Borthwick Kathleen been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($38K) across all tracked filings.
Where can I see all of Borthwick Kathleen's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
